Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Lopert, M. Moon (2007)
Toward a rational, value-based drug benefit for Medicare.Health affairs, 26 6
L. Jarvis (2007)
BIOTECH CHALLENGES: Earnings drop in THIRD QUARTER at both Amgen and Biogen but increase 22% at GenentechChemical & Engineering News, 85
C. Truelove
Necessary steps
Aaron Catlin, C. Cowan, Micah Hartman, S. Heffler (2008)
National health spending in 2006: a year of change for prescription drugs.Health affairs, 27 1
C. Duffield (1988)
The Delphi technique.The Australian journal of advanced nursing : a quarterly publication of the Royal Australian Nursing Federation, 6 2
G. Vinten (2007)
Excessive Medical Spending: Facing the ChallengeJournal of The Royal Society for The Promotion of Health, 127
L. Fabrigar, D. Wegener, R. Maccallum, E. Strahan (1999)
Evaluating the use of exploratory factor analysis in psychological research.Psychological Methods, 4
V. Ozdemir, B. Williams-Jones (2006)
Democracy unleashed—unpacking the tooth fairy in drug industry R&DNature Biotechnology, 24
L.M. Jarvis
Biotech challenges
R. Steinbrook (2007)
Election 2008 - campaign contributions, lobbying, and the U.S. Health Sector.The New England journal of medicine, 357 8
J. Tucker, Seth Yakatan, Stan Yakatan (2008)
Biogenerics 2007: How far have we come?Journal of Commercial Biotechnology, 14
US Government Accountability Office
New Drug Development: Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts
L. Jarvis (2007)
PHARMA’S TOUGH BALANCING ACT: Weaker third-quarter earning at the major drug companies reflect DRUG WITHDRAWALS and generic competitionChemical & Engineering News, 85
J. DiMasi, R. Hansen, H. Grabowski (2003)
The price of innovation: new estimates of drug development costs.Journal of health economics, 22 2
S. Thangaratinam, Charles Redman (2005)
The Delphi techniqueThe Obstetrician & Gynaecologist, 7
D. Carpenter, Zucker Ej, Avorn Drug-review (2008)
FDA Drug Review Deadlines: A Safety Concern?
G. Vinten (2007)
Book Review: Exce$$ive Medical $pending: Facing the challenge Edited by Norman J Temple and Andrew Thompson. Published by Radcliffe Publishing Ltd, Oxford and Seattle 2007. Paperback. 216pp. Price £29.95 or $49.95. ISBN 1 84619 168 8The Journal of The Royal Society for the Promotion of Health, 127
G. Anderson, D. Juurlink, A. Detsky (2008)
Newly approved does not always mean new and improved.JAMA, 299 13
M. Olson (2002)
Pharmaceutical Policy Change and the Safety of New Drugs*The Journal of Law and Economics, 45
J. Yager, R. Starrett (2006)
Issues Facing Development of New Innovative MedicinesDrug information journal : DIJ / Drug Information Association, 40
Xiaotian Zhong, George Moseley (2007)
Mission possible: managing innovation in drug discoveryNature Biotechnology, 25
J. Leiden (2008)
Canaries, coal mines and the drug supplyNature Biotechnology, 26
Heidi Rajamäki (2008)
Anticipating and managing the challenges of biotechnology marketingJournal of Commercial Biotechnology, 14
L.M. Jarvis
Pharma's tough balancing act
J. DiMasi, H. Grabowski (2007)
The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 28
L. Klein
Navigating restricted waters
J. Patterson
Can big Pharma produce the next generation of medicines?
J. Lounsbury (1991)
As I See It
Purpose – The pharmaceutical industry faces significant challenges in the immediate future, including drug safety, intellectual property in emerging markets, industry image, and the overall effect of marketing. To remain effective, pharmaceutical executives must translate these challenges to the industry into solutions, find relationships between individual issues, and group these issues into larger themes. The purpose of this paper is to study the issues that senior industry executives perceive the pharmaceutical industry faces and how they can organize these issues into high‐impact “pressure points.” Design/methodology/approach – Using a modified approach to the Delphi technique, 70 senior pharmaceutical industry executives rated issues facing the pharmaceutical industry. Their responses were then examined using factor analysis. Findings – The study concludes that concerns about the industry's future must be accompanied by a concerted effort to communicate and market the importance drugs play in improving and extending lives. Practical implications – These will influence political factors that effect new drug development. Originality/value – The study develops a list of potential major issues facing the industry over the next three to five years.
International Journal of Pharmaceutical and Healthcare Marketing – Emerald Publishing
Published: Apr 3, 2009
Keywords: Pharmaceuticals industry; Drugs; Research and development
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.